10x Genomics Q1 revenue $114.5M (+8% YoY); net loss widens to $42.4M; FY22 guidance maintained

10x Genomics, Inc.

2022-Q1 EPS reported -$0.38 revenue$114,496,000

Revenue $114.5M, up 8% YoY from $105.8M; gross margin fell to 78% from 84%.
Net loss $42.4M vs $11.6M in Q1 2021; operating loss $41.7M including $26.0M stock-based comp.
Operating expenses rose 32% to $130.8M driven by higher personnel, R&D, and infrastructure costs.
Cash and marketable securities $539.3M as of March 31, 2022.
Full-year 2022 revenue guidance maintained at $600M-$630M, implying 22-28% growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.